[
    [
        {
            "time": "2020-08-09",
            "original_text": "贝达药业：盐酸恩沙替尼EXalt3研究中期分析结果发布或成为公司第一个在全球上市的创新药",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸恩沙替尼",
                    "EXalt3研究",
                    "中期分析结果",
                    "全球上市",
                    "创新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：盐酸恩沙替尼EXalt3研究中期分析结果发布或成为公司第一个在全球上市的创新药",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]